CNS Pharmaceuticals, Inc. (CNSP) vs Skye Bioscience, Inc. (SKYE)

A side-by-side comparison of CNS Pharmaceuticals, Inc. and Skye Bioscience, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — CNSP vs SKYE

growth of $100 · dividends reinvested · last 7y
CNSP -100.0% (-85.6%/yr)SKYE -99.7% (-56.6%/yr)SKYE compounded faster over this window
Log scale — wide-divergence pair
000001101001kStart $100202120232025$0$0
CNSP SKYE

CNSP vs SKYE: by the numbers

  • •CNSP is the larger company ($8M vs $7M market cap).

Metrics side by side

Valuation

MetricCNSPSKYE
P/B ratio0.44N/A

Profitability

MetricCNSPSKYE
Gross margin0.00%0.00%
Operating margin0.00%0.00%
Net margin0.00%0.00%
ROE-91.75%N/A
ROIC-92.94%N/A

Growth (annualized)

MetricCNSPSKYE
Total return CAGR (5Y)-91.63%-60.42%

Frequently asked

How have CNSP and SKYE total returns compared?
Over the past 5 years, CNSP delivered -91.63% and SKYE delivered -60.42% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.